Assessment of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) among U.S. community hematologists/oncologists (cH/O)

Nov 21, 2023, 11:27 AM

Title : Assessment of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) among U.S. community hematologists/oncologists (cH/O)